Fundz
Following Biocytogen Pharmaceuticals (Beijing) Ltd?

Get the free weekly contract digest

The latest new contracts, like Biocytogen Pharmaceuticals (Beijing) Ltd’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload BsADC Program

Jul 31, 2024almost 2 years ago

Contract Type

agreement

BeijingBiotechnology

Description

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has entered into an option and license agreement for a potential first-in-class B7H3/PTK7 BsADC program with IDEAYA Biosciences, Inc. The partnership aims to explore the combination of potential first-in-class ADC and IDEAYA’s DDR small molecules to enhance the precision and potency of ADCs.

Company Information

Company

Biocytogen Pharmaceuticals (Beijing) Ltd

Location

Beijing, Beijing, China

About

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotech company focusing on the discovery of novel antibody/ADC therapeutics.

Predictive Intelligence
Strategic

ML-powered predictions for Biocytogen Pharmaceuticals (Beijing) Ltd's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.